Clinical Trial Update: Tocilizumab for Patients With Cancer and COVID-19 Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tocilizumab in cancer patients with COVID-19 was terminated; results were posted in June 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Malignant Solid Neoplasm
• Pneumonia
• Pneumonitis
• Respiratory Distress Syndrome

Drugs mentioned

• Actemra (tocilizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Status: TERMINATED | Results posted: 2021-06-04